MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL

File: 123096_sep96_decls28_0018.txt
Page: 0018
Total Pages: 40

Subject: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                     

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003203

Folder Title: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                                                     

Document Number:          1

Folder Seq  #:         47



                                        UNCLASSIFIED








           organisms by aerosol or intradermal routes), ulceroglandular,
           typhoidal or pharyngeal forms could be seen. Ulceroglandular
           tularemia generally occurs about 3 days after exposure (range,
           2-10 days), and manifests as a cutaneous ulcer with regional
           lymphadenopathy, fever, chills, headache, and malaise. With
           typhoidal disease, the systemic clinical manifestations are
           similar to those seen in the ulceroglandular form, but the
           disease is not "contained" as a localized lesion. Typhoidal
           disease occurs after inhalation of tularemia organisms; in the
           latter, clinically and radiologically evident pneumonia may be
           significant. Three to five days following inhalation, the
           abrupt onset of fever, chills, headache, myalgia, and
           prostration are seen, with a non-productive cough. Deposition
           of organisms in the orophyarynx may also produce a pharynygeal
           form of tularemia, with "ulceroglandular" type lesions
           localized to the throat.





              0 Specific Laboratory DiagnQsis. identification of
              organisms by staining ulcer fluids or sputum is generally
              not helpful. Routine culture is difficult due to unusual
              growth requirements or overgrowth of commensual bacteria.
              The diagnosis can be established retrospectively by serology.


                  . Streptomycin is the treatment of choice. Gentamycin
           is also effective. Although laboratory-related infections with
           this organism are very common, human-to-human spread is unusual.


                         A live-attenuated tularemia vaccine is available
           as in investigational new drug (IND). This vaccine has been
           administered to more than 5,000 persons without significant
           adverse reactions, and is of proven effectiveness in preventing
         laboratory-acquired typhoidal and pneumonic tularemia.

              The use of antibiotics for prophylaxis against tularemia is
           controversial. At best, onset of disease will be delayed
           somewhat.








                                          16




                                       UNCLASSIFIED

Document 40 f:/Week-36/BX003203/MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL/medical defense against biological material:12179609282229
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Folder Seq # = 47
Subject = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 17-DEC-1996